NSE · ZYDUSLIFE
Zydus Lifesciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,872 Cr with net profit ₹340 Cr — a 11.82% net margin, versus 18.22% the period before.
Shareholding
As of 2026-06-30
- Promoter75.01%
- Public6.83%
- FII6.88%
- DII11.27%
3,99,251 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.44× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #2 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,41,478 Cr | 34.94 | 5.29 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd.(this company) | ₹1,11,631 Cr | 22.86 | 4.12 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,353 Cr | 30.84 | 3.2 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,06,387 Cr | 97.28 | 20.09 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹97,282 Cr | 30.19 | 2.55 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹96,652 Cr | 25.56 | 2.54 | 9.25% | 10.7% |
| Lupin Limited | ₹95,797 Cr | 16.08 | 4.27 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹94,174 Cr | 44.14 | 5.77 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,276 Cr | 21.88 | 6.49 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,713 Cr | 87.27 | 1.85 | 1.14% | 2.89% |
AI analysis
AI-generated · google/gemini-2.5-flashZydus Lifesciences Ltd. operates with a market capitalization of Rs 114613 Cr. The company achieved a revenue of Rs 23511 Cr with a profit margin of 18.86%. Its earnings per share stood at Rs 54.46, and its book value was Rs 271.78. The debt-to-equity ratio is 0.31, and it offers a dividend yield of 9%.
Positives
- +The company reported a substantial revenue growth of 18.9%.
- +The return on capital employed (ROCE) is 24.56%, indicating efficient use of capital.
- +The debt-to-equity ratio is low at 0.31.
- +Promoter shareholding is stable at 75.0146% with no pledged shares.
Negatives
- −No quarterly EPS figures have been disclosed for any period in the provided data.
- −There is no information regarding the company's specific business activities.
- −There are no quarterly results disclosed for periods after Mar 2026.
- −The company's PE ratio of 21.1 is higher than its book value per share of Rs 271.78.
Financial Performance
Zydus Lifesciences Ltd. reported an annual revenue of Rs 23511 Cr for the period ending Mar 2025, demonstrating revenue growth of 18.9%. The net profit for the same period was Rs 4525.5 Cr. Quarterly revenue for Mar 2026 was Rs 7587 Cr, with a net profit of Rs 1272.5 Cr. The EBITDA for Mar 2025 was Rs 6412.2 Cr.
Profitability & Returns
The company's profit margin stood at 18.86%. It generated a return on equity (ROE) of 18.59% and a return on capital employed (ROCE) of 24.56%. The earnings per share (EPS) for Mar 2025 was Rs 44.97, while the latest reported EPS is Rs 54.46.
Balance Sheet
Zydus Lifesciences Ltd. has a book value of Rs 271.78. The debt-to-equity ratio is 0.31, indicating a manageable level of debt relative to equity. There are no reported promoter pledges.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Zydus Lifesciences Ltd. was 75.0146%. DIIs held 11.2749% and FIIs held 6.883%. Public shareholding was 6.8275%. The company has no reported promoter share pledges.
Data as of — price: 2026-09-12 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.